The impact of race and ethnicity in breast cancer: disparities and implications for precision oncology

Accepted/In Press date: 14 January 2022

e-pub ahead of print date: 11 February 2022

Additional Information: Funding Information: SHP reports consultancy/advisory role for AstraZeneca, Pfizer, Eisai, Roche, Daiichi-Sankyo, Eli Lilly, and Novartis Pharmaceuticals; patents and royalties from Hanmi; honoraria from AstraZeneca, Pfizer, Eisai, Roche, Daiichi-Sankyo, and Novartis; and grant/research funding from AstraZeneca, Merck, Pfizer, Novartis, Alteogen, and Roche. EC reports honorarium from Astra-Zeneca, Novartis, Pfizer, Roche, and Lilly; advisory board participation for Pfizer, Nanostring, and Lilly; and expert panel participation for World Cancer Research Fund. RIC and EC report institutional research funding from SECA SAI is a recipient of research funds from AstraZeneca Inc., Roche, and Pfizer and has consultant and advisory roles for Amen, AstraZeneca, Eisai, Hanmi Corp., Lilly, Novartis, Pfizer, and Roche. The other authors declare that they have no competing interests. We acknowledge Professor Diana Eccles, the chief investigator of the POSH study, the POSH collaborators, and all the patients who participated in the POSH study. Funding for the POSH study has been provided by the Wessex Cancer Trust, Cancer Research UK (grant refs A7572, A11699, C22524); the study is a National Cancer Research Network Portfolio study.

Keywords: BRCA mutations, Breast cancer, CDK4/6 inhibitors, Clinical outcomes, Disparities, Ethnicity, PARP inhibitors, Precision oncology, Race, Socioeconomic status, Targeted therapy

Local EPrints ID: 473595

URI: http://eprints.soton.ac.uk/id/eprint/473595

DOI: doi:10.1186/s12916-022-02260-0

ISSN: 1741-7015

PURE UUID: 6677557f-2bdf-4d89-a922-09bf22bf6bc1

Date deposited: 24 Jan 2023 17:43

Last modified: 16 Mar 2024 23:45